Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
<h4>Background</h4> We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. <h4>Methods and findings</h4> In this randomised, observer...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7f50b4c25b664eea9599a273130f7e74 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7f50b4c25b664eea9599a273130f7e74 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Houreratou Barry Gaudensia Mutua Hannah Kibuuka Zacchaeus Anywaine Sodiomon B. Sirima Nicolas Meda Omu Anzala Serge Eholie Christine Bétard Laura Richert Christine Lacabaratz M. Juliana McElrath Stephen De Rosa Kristen W. Cohen Georgi Shukarev Cynthia Robinson Auguste Gaddah Dirk Heerwegh Viki Bockstal Kerstin Luhn Maarten Leyssen Macaya Douoguih Rodolphe Thiébaut the EBL2002 Study group Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa |
| description |
<h4>Background</h4> We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. <h4>Methods and findings</h4> In this randomised, observer-blind, placebo-controlled Phase II trial, 668 healthy 18- to 70-year-olds and 142 HIV-infected 18- to 50-year-olds were enrolled from 1 site in Kenya and 2 sites each in Burkina Faso, Cote d’Ivoire, and Uganda. Participants received intramuscular Ad26.ZEBOV followed by MVA-BN-Filo at 28-, 56-, or 84-day intervals, or saline. Females represented 31.4% of the healthy adult cohort in contrast to 69.7% of the HIV-infected cohort. A subset of healthy adults received booster vaccination with Ad26.ZEBOV or saline at Day 365. Following vaccinations, adverse events (AEs) were collected until 42 days post last vaccination and serious AEs (SAEs) were recorded from signing of the ICF until the end of the study. The primary endpoint was safety, and the secondary endpoint was immunogenicity. Anti-Ebola virus glycoprotein (EBOV GP) binding and neutralising antibodies were measured at baseline and at predefined time points throughout the study. The first participant was enrolled on 9 November 2015, and the date of last participant’s last visit was 12 February 2019. No vaccine-related SAEs and mainly mild-to-moderate AEs were observed among the participants. The most frequent solicited AEs were injection-site pain (local), and fatigue, headache, and myalgia (systemic), respectively. Twenty-one days post-MVA-BN-Filo vaccination, geometric mean concentrations (GMCs) with 95% confidence intervals (CIs) of EBOV GP binding antibodies in healthy adults in 28-, 56-, and 84-day interval groups were 3,085 EU/mL (2,648 to 3,594), 7,518 EU/mL (6,468 to 8,740), and 7,300 EU/mL (5,116 to 10,417), respectively. In HIV-infected adults in 28- and 56-day interval groups, GMCs were 4,207 EU/mL (3,233 to 5,474) and 5,283 EU/mL (4,094 to 6,817), respectively. Antibody responses were observed until Day 365. Ad26.ZEBOV booster vaccination after 1 year induced an anamnestic response. Study limitations include that some healthy adult participants either did not receive dose 2 or received dose 2 outside of their protocol-defined interval and that the follow-up period was limited to 365 days for most participants. <h4>Conclusions</h4> Ad26.ZEBOV, MVA-BN-Filo vaccination was well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These data supported the approval by the European Union for prophylaxis against EBOV disease in adults and children ≥1 year of age. <h4>Trial registration</h4> ClinicalTrials.govNCT02564523 Houreratou Barry and co-workers report on safety and immunogenicity of an Ebola vaccine in adults across four African countries. Author summary <h4>Why was this study done?</h4> With Ebola outbreaks increasing, there is an unmet medical need for a prophylactic vaccine to prevent and mitigate Ebola outbreaks. To address the urgent medical need during the 2014 to 2016 outbreak, the clinical development of the 2-dose vaccine regimen comprising of Ad26.ZEBOV and MVA-BN-Filo was accelerated. This Phase II study was part of this accelerated program, evaluating the safety and immunogenicity of the 2-dose vaccine regimen in healthy and HIV-infected African adults, with 28-, 56-, and 84-day intervals between doses. The study was amended to evaluate safety and immunogenicity of a booster vaccination with Ad26.ZEBOV, administered approximately 1 year after the first vaccination, in healthy adults. <h4>What did the researchers do and find?</h4> We conducted a randomised trial to assess the safety and the immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in 3 different vaccination intervals in healthy and HIV-infected adults. The vaccine regimen was well tolerated and induced marked immune responses; the highest humoral responses were observed after vaccination with 56-day and 84-day intervals. Anamnestic responses were observed in all healthy participants receiving Ad26.ZEBOV as booster at 1 year after the first dose. <h4>What do these findings mean?</h4> Our results demonstrate that the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen is safe and immunogenic in healthy and HIV-infected adults and induces immune memory that can rapidly be reactivated. Our findings support the prophylactic use of the 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola infection in African adult populations. The 2-dose vaccine regimen comprising of Ad26.ZEBOV and MVA-BN-Filo has received marketing authorisation under exceptional circumstances for prophylactic use against EVD in adults and children ≥1 year old within the European Union. |
| format |
article |
| author |
Houreratou Barry Gaudensia Mutua Hannah Kibuuka Zacchaeus Anywaine Sodiomon B. Sirima Nicolas Meda Omu Anzala Serge Eholie Christine Bétard Laura Richert Christine Lacabaratz M. Juliana McElrath Stephen De Rosa Kristen W. Cohen Georgi Shukarev Cynthia Robinson Auguste Gaddah Dirk Heerwegh Viki Bockstal Kerstin Luhn Maarten Leyssen Macaya Douoguih Rodolphe Thiébaut the EBL2002 Study group |
| author_facet |
Houreratou Barry Gaudensia Mutua Hannah Kibuuka Zacchaeus Anywaine Sodiomon B. Sirima Nicolas Meda Omu Anzala Serge Eholie Christine Bétard Laura Richert Christine Lacabaratz M. Juliana McElrath Stephen De Rosa Kristen W. Cohen Georgi Shukarev Cynthia Robinson Auguste Gaddah Dirk Heerwegh Viki Bockstal Kerstin Luhn Maarten Leyssen Macaya Douoguih Rodolphe Thiébaut the EBL2002 Study group |
| author_sort |
Houreratou Barry |
| title |
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa |
| title_short |
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa |
| title_full |
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa |
| title_fullStr |
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa |
| title_full_unstemmed |
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa |
| title_sort |
safety and immunogenicity of 2-dose heterologous ad26.zebov, mva-bn-filo ebola vaccination in healthy and hiv-infected adults: a randomised, placebo-controlled phase ii clinical trial in africa |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/7f50b4c25b664eea9599a273130f7e74 |
| work_keys_str_mv |
AT houreratoubarry safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT gaudensiamutua safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT hannahkibuuka safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT zacchaeusanywaine safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT sodiomonbsirima safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT nicolasmeda safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT omuanzala safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT sergeeholie safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT christinebetard safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT laurarichert safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT christinelacabaratz safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT mjulianamcelrath safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT stephenderosa safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT kristenwcohen safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT georgishukarev safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT cynthiarobinson safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT augustegaddah safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT dirkheerwegh safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT vikibockstal safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT kerstinluhn safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT maartenleyssen safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT macayadouoguih safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT rodolphethiebaut safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica AT theebl2002studygroup safetyandimmunogenicityof2doseheterologousad26zebovmvabnfiloebolavaccinationinhealthyandhivinfectedadultsarandomisedplacebocontrolledphaseiiclinicaltrialinafrica |
| _version_ |
1718445221830721536 |
| spelling |
oai:doaj.org-article:7f50b4c25b664eea9599a273130f7e742021-11-04T05:38:56ZSafety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa1549-12771549-1676https://doaj.org/article/7f50b4c25b664eea9599a273130f7e742021-10-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555783/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4> We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. <h4>Methods and findings</h4> In this randomised, observer-blind, placebo-controlled Phase II trial, 668 healthy 18- to 70-year-olds and 142 HIV-infected 18- to 50-year-olds were enrolled from 1 site in Kenya and 2 sites each in Burkina Faso, Cote d’Ivoire, and Uganda. Participants received intramuscular Ad26.ZEBOV followed by MVA-BN-Filo at 28-, 56-, or 84-day intervals, or saline. Females represented 31.4% of the healthy adult cohort in contrast to 69.7% of the HIV-infected cohort. A subset of healthy adults received booster vaccination with Ad26.ZEBOV or saline at Day 365. Following vaccinations, adverse events (AEs) were collected until 42 days post last vaccination and serious AEs (SAEs) were recorded from signing of the ICF until the end of the study. The primary endpoint was safety, and the secondary endpoint was immunogenicity. Anti-Ebola virus glycoprotein (EBOV GP) binding and neutralising antibodies were measured at baseline and at predefined time points throughout the study. The first participant was enrolled on 9 November 2015, and the date of last participant’s last visit was 12 February 2019. No vaccine-related SAEs and mainly mild-to-moderate AEs were observed among the participants. The most frequent solicited AEs were injection-site pain (local), and fatigue, headache, and myalgia (systemic), respectively. Twenty-one days post-MVA-BN-Filo vaccination, geometric mean concentrations (GMCs) with 95% confidence intervals (CIs) of EBOV GP binding antibodies in healthy adults in 28-, 56-, and 84-day interval groups were 3,085 EU/mL (2,648 to 3,594), 7,518 EU/mL (6,468 to 8,740), and 7,300 EU/mL (5,116 to 10,417), respectively. In HIV-infected adults in 28- and 56-day interval groups, GMCs were 4,207 EU/mL (3,233 to 5,474) and 5,283 EU/mL (4,094 to 6,817), respectively. Antibody responses were observed until Day 365. Ad26.ZEBOV booster vaccination after 1 year induced an anamnestic response. Study limitations include that some healthy adult participants either did not receive dose 2 or received dose 2 outside of their protocol-defined interval and that the follow-up period was limited to 365 days for most participants. <h4>Conclusions</h4> Ad26.ZEBOV, MVA-BN-Filo vaccination was well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These data supported the approval by the European Union for prophylaxis against EBOV disease in adults and children ≥1 year of age. <h4>Trial registration</h4> ClinicalTrials.govNCT02564523 Houreratou Barry and co-workers report on safety and immunogenicity of an Ebola vaccine in adults across four African countries. Author summary <h4>Why was this study done?</h4> With Ebola outbreaks increasing, there is an unmet medical need for a prophylactic vaccine to prevent and mitigate Ebola outbreaks. To address the urgent medical need during the 2014 to 2016 outbreak, the clinical development of the 2-dose vaccine regimen comprising of Ad26.ZEBOV and MVA-BN-Filo was accelerated. This Phase II study was part of this accelerated program, evaluating the safety and immunogenicity of the 2-dose vaccine regimen in healthy and HIV-infected African adults, with 28-, 56-, and 84-day intervals between doses. The study was amended to evaluate safety and immunogenicity of a booster vaccination with Ad26.ZEBOV, administered approximately 1 year after the first vaccination, in healthy adults. <h4>What did the researchers do and find?</h4> We conducted a randomised trial to assess the safety and the immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in 3 different vaccination intervals in healthy and HIV-infected adults. The vaccine regimen was well tolerated and induced marked immune responses; the highest humoral responses were observed after vaccination with 56-day and 84-day intervals. Anamnestic responses were observed in all healthy participants receiving Ad26.ZEBOV as booster at 1 year after the first dose. <h4>What do these findings mean?</h4> Our results demonstrate that the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen is safe and immunogenic in healthy and HIV-infected adults and induces immune memory that can rapidly be reactivated. Our findings support the prophylactic use of the 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola infection in African adult populations. The 2-dose vaccine regimen comprising of Ad26.ZEBOV and MVA-BN-Filo has received marketing authorisation under exceptional circumstances for prophylactic use against EVD in adults and children ≥1 year old within the European Union.Houreratou BarryGaudensia MutuaHannah KibuukaZacchaeus AnywaineSodiomon B. SirimaNicolas MedaOmu AnzalaSerge EholieChristine BétardLaura RichertChristine LacabaratzM. Juliana McElrathStephen De RosaKristen W. CohenGeorgi ShukarevCynthia RobinsonAuguste GaddahDirk HeerweghViki BockstalKerstin LuhnMaarten LeyssenMacaya DouoguihRodolphe Thiébautthe EBL2002 Study groupPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 18, Iss 10 (2021) |